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A B S T R A C T
Ceramide is emerging as one of the players of inflammation in lung diseases. However, data on its inflammatory
role in Cystic Fibrosis (CF) as part of the extracellular machinery driven by lung mesenchymal stem cells (MSCs)-
derived extracellular vesicles (EVs) are missing.
We obtained an in vitromodel of CF-MSC by treating control human lung MSCs with a specific CFTR inhibitor.
We characterized EVs populations derived from MSCs (ctr EVs) and CF-MSCs (CF-EVs) and analyzed their
sphingolipid profile by LC–MS/MS. To evaluate their immunomodulatory function, we treated an in vitro human
model of CF, with both EVs populations.
Our data show that the two EVs populations differ for the average size, amount, and rate of uptake. CF-EVs
display higher ceramide and dihydroceramide accumulation as compared to control EVs, suggesting the in-
volvement of the de novo biosynthesis pathway in the parental CF-MSCs. Higher sphingomyelinase activity in CF-
MSCs, driven by inflammation-induced ceramide accumulation, sustains the exocytosis of vesicles that export
new formed pro-inflammatory ceramide.
Our results suggest that CFTR dysfunction associates with an enhanced sphingolipid metabolism leading to
the release of EVs that export the excess of pro-inflammatory Cer to the recipient cells, thus contributing to
maintain the unresolved inflammatory status of CF.
1. Introduction
Long considered structural and metabolic molecules, sphingolipids
(SPLs) have been recognized as signaling mediators. SPLs are localized
in the plasma and in intracellular organelle membranes, with ceramide
(Cer) being the structural unit of membrane-forming SPLs and the main
modulator of cellular processes such as cell growth, cell death and in-
flammation (Hannun and Obeid, 2008; Chiricozzi et al., 2018). Cer can
derive from the de novo biosynthesis pathway or from the so-called
salvage pathway via degradation of complex SPLs, such as sphingo-
myelin (SM), the most abundant membrane lipid (Gault et al., 2010;
Marchesini and Hannun, 2004). Among sphingolipids, Cer is emerging
as one of the players of the pulmonary dysfunction in inflammatory
lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD)
and Cystic Fibrosis (CF) (Petrache and Petrusca, 2013; Grassme et al.,
2013). Its accumulation in the airways of CFTR-deficient mice, is re-
lated to pulmonary inflammation, death of epithelial cells, and sus-
ceptibility to severe P. aeruginosa infections in mice and in human
(Teichgraber et al., 2008; Riethmuller et al., 2009; Becker et al., 2010).
We previously demonstrated that the de novo ceramide synthesis con-
tributes to lung inflammation and P. aeruginosa infection in a murine CF
model (Caretti et al., 2014). Moreover, we observed that reducing
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ceramide accumulation in CF airways, correlates with an up-regulation
of the anti-oxidative response of the transcriptional factor NRF2, even
under infection by A. fumigatus (Caretti et al., 2016) and with a down-
regulation of the pro-inflammatory cytokine release (Caretti et al.,
2014).
Mesenchymal stem cells (MSCs) are multipotent non-hematopoietic
stem cells residing in many tissues, including the lung, with an emer-
gent role in the attenuation of inflammation mainly due to the release
of extracellular vesicles (EVs). EVs are membrane-derived particles that
comprise both exosomes and microvesicles (MVs). Exosomes are gen-
erated inside multivesicular bodies (MVB) and are generally 30–100 nm
in diameter. Microvesicles are derived from the plasma membrane and
are generally larger than exosomes, ranging from 100 to 300 nm. They
are involved in intercellular communication since they carry a large
array of bioactive molecules including proteins, mRNA, miRNA and
bioactive lipids to distant cells (Fatima et al., 2017; Dostert et al.,
2017). We have recently demonstrated the role of EVs produced by
human lung MSCs in controlling inflammation process. In an in vitro CF
bronchial epithelial cellular model, EVs treatment reduces transcription
and protein expression of pro-inflammatory cytokines such as IL-1β, IL-
8, IL-6, under basal and TNFα stimulated conditions. This effect could
be mediated by up-regulation of the PPARγ axis, whose down-stream
effectors (NF-kB and HO-1) are well-known modulators of in-
flammatory and oxidative stress pathways (Zulueta et al., 2018).
SPLs participate in EVs biogenesis and in EVs activity towards target
cells, as reviewed by Verderio C. and colleagues (Verderio et al., 2018).
Cer derived from SM hydrolysis, promoted by neutral sphingomyelinase
2 (n-SMase2), drives exosomes formation and transport via an ESCRT-
independent pathway (Trajkovic et al., 2008). Secretion of neuron-de-
rived exosomes was modulated by the activities of sphingolipid-meta-
bolizing enzymes, including nSMase2, in Alzheimer disease models
(Yuyama et al., 2012; Dinkins et al., 2014). As for MVs, the acid
sphingomyelinase generates Cer that in turn triggers MVs budding from
the plasma membrane (Bianco et al., 2009). SM to Cer conversion alters
membrane curvature and fluidity, driving membrane evagination of
MVs by means of redistribution of inverted cone-shaped Cer molecules
(Subra et al., 2007). Several lines of evidence indicate Cer-enriched
exosomes as mediators of cytotoxic effects in target cells. Primary cul-
tured astrocytes secrete prostate apoptosis response 4 (PAR-4)/cer-
amide-enriched exosomes that represent a novel mechanism of Aβ-de-
pendent apoptosis in Alzheimer disease (Wang et al., 2012). More
recently, Podbielska M. and colleagues, demonstrated the pro-apoptotic
potential of Cer-enriched exosomes released by a human oligoden-
droglioma cell line previously stimulated with inflammatory cytokines
(Podbielska et al., 2016).
In the present manuscript, we investigated the hypothesis that lung
MSCs and MSCs-derived EVs could be immunologically impaired in CF,
partially because of altered SPLs content. By means of an in vitro model
of CF-MSCs, we found higher ceramide and dihydroceramide (dhCer)
content in EVs shed from CF-MSCs (CF-EVs) than in control MSCs-de-
rived EVs (ctr EVs), with C16:0 and the long acyl chain ceramides
(C22:0; C24:0; C24:1) being the most representative. Moreover, the two
EV populations are different in term of average size, amount, and rate
of uptake by the recipient cells. As for parental MSCs, total Cer and
sphingomyelin content significantly increased and decreased, respec-
tively. By treating IB3-1, a bronchial epithelial cell line derived from a
CF patient, with CF-EVs or ctr EVs, we observed that CF-EVs are less
efficient in decreasing pro-inflammatory cytokines expression. Overall,
we observed an inverse correlation between the anti-inflammatory ef-
ficacy of EVs and their Cer content.
In conclusion, our data suggest that lung MSCs compartment may be
immunologically altered in CF thus contributing to maintain the
chronic, unresolved pulmonary inflammation.
2. Materials and methods
2.1. Reagents and antibodies
The following materials were purchased: bFGF and TNFα from
Peprotech LTD (Israel); LHC Basal, LHC-8 w/o gentamicin culture
media from Gibco (US); FBS and DMEM from Euro Clone Life Science
Division (Italy); protease inhibitors (Roche Italia, Italy); CellBrite Green
Cytoplasmic Membrane Dye (Biotium, US); SYBR Green system
(Qiagen, Italy); synthetic oligonucleotides from M-Medical (Italy), I-
172 CFTR inhibitor (Sigma Aldrich, DE). Methanol, acetonitrile, am-
monium formate, acetic acid, potassium hydroxide and formic acid (all
analytical grade) were supplied from Merck (Darmstadt, Germany).
Water was MilliQ grade. Sphingolipids standards were purchased by
Avanti Polar Lipids (Alabaster, USA). Primary antibodies: anti- PPARγ
(ElabScience, US), anti-H3 (Cell Signaling, US), anti-β-actin (Sigma,
US), anti-CFTR Type A4 (596) (University of North Carolina – Chapel
Hill, UNC-CH, on behalf of Cystic Fibrosis Foundation, USA), anti-HO-1
(Abcam, UK), anti-caspase 9 (Cell Signaling, US), anti-LC3 (Cell
Signaling, US). The secondary antibodies were from Jackson
Laboratories (Bar Harbor, ME, US). All reagents were of the maximal
available purity degree.
2.2. Ethic statements
Human lung mesenchymal stem cells (MSCs) were isolated from
lung biopsies obtained from seven patients that underwent lung surgery
for suspected bullous emphysema or lung tumor. Tissues were obtained
under appropriate approval by the Ethical Committee of the ASST Santi
Paolo e Carlo, Milano, Area A (n°2211, 12/14/2016). All participants
signed informed consent forms approved by the Ethical Committee
before surgery and specimen collection. All the procedures followed the
Declaration of Helsinki protocols.
2.3. Isolation and treatment of human lung MSCs
Human lung MSCs were isolated and cultured as previously de-
scribed (Zulueta et al., 2018). Briefly, lung samples were recovered
after planned surgery for non infectious diseases (bullous and tumor
lesions). Each lung biopsy of about 1 cm3, was minced with surgical
scissors and maintained in DMEM medium containing 18% FBS and 1%
penicillin/streptomycin at 37 °C in a humid atmosphere containing 5%
CO2 for ten days. At day tenth, the adherent cells were cultured con-
tinuously in the presence of bFGF (5 ng/mL) until the passage seven. To
obtain an in vitro model of Cystic Fibrosis MSCs (CF-MSCs), control
MSCs (ctr MSCs) were treated with 10 μg/ml of I-172 CFTR inhibitor for
48 h, as reported by Mattoscio et al (Mattoscio et al., 2010). Control
MSCs are intended as treated with dimethyl sulfoxide (DMSO), the I-
172 CFTR inhibitor’s solvent.
2.4. Isolation of Extracellular vesicles (EVs) derived from human lung
MSCs
EVs were obtained from the supernatants of both ctr- and CF-MSCs
cultures (ctr EVs and CF-EVs, respectively) after 48–72 hours, by ul-
tracentrifugation as previously described (Bonzini et al., 2017). After
serial centrifugations (1000, 2000 and 3000 g for 15min at 4 °C), su-
pernatants were centrifuged at 110,000 g (Beckman Coulter Optima L-
90 K ultracentrifuge) for 75min at 4 °C. EVs were resuspended ac-
cording to the final MSCs number (10 μl per 1× 106 cells).
2.5. Cell line and treatments
IB3-1 cells, an adeno-associated virus-transformed human bronchial
epithelial cell line derived from a CF patient (ΔF508/W1282X) pro-
vided by LGC Promochem (US), were grown in LHC-8 medium
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supplemented with 5% FBS, 1% penicillin/streptomycin at 37 °C and
5% CO2. For the treatments, 2.5× 105 cells/well in 3mL medium were
plated in 6-well tissue culture dishes for twenty-four hours. Then, the
medium was replaced with fresh one (control group), or supplemented
with 30 μL of EVs derived from either control or CF-MSCs (ctr EVs and
CF-EVs group, respectively) for 24 h. Cells were then harvested to
perform different assays. Cell viability was evaluated by Trypan blue
exclusion test as previously reported (Fabiani et al., 2017).
2.6. EV uptake
Five millions ctr MSCs and CF-MSCs were labeled with CellBrite
Green Cytoplasmic Membrane Dye (Biotium) according to the manu-
facturer’s instructions and supernatants were collected after 72 h and
used to isolate EVs’ populations by ultracentrifugation. IB3-1 cells were
seeded in 24-well culture plates and treated for 16 h with 100 μL of
either ctr- or CF-EVs suspension obtained by resuspension in 500 μL of
IB3-1 cell medium. Then, the cells were trypsinized and analyzed by
flow cytometry.
2.7. Nanoparticle tracking analysis (NTA) of EVs
The size and total number of EVs were calculated with the tech-
nology of Nanoparticle Tracking Analysis (NTA) that allows measuring
the Brownian motion of suspended vesicles (Pergoli et al., 2017). By
using the NanoSight NS300 system (Amesbury, UK), five 30-s record-
ings were made for each sample and the data were analyzed with NTA
software. In order to eliminate the presence of vesicles derived from
FBS in the medium, EVs samples were obtained from ctr- and CF-MSCs
cultured in FBS free medium for 24 h. The results are provided as high-
resolution particle-size distribution and particles concentration.
2.8. Laser light scattering analysis of EVs
Parallel Dynamic and Static Laser Light Scattering (DLS and SLS)
experiments were performed on a home-made apparatus equipped with
four optical channels, to reach high sensitivity (Lago and Rovati, 1993).
Samples were inserted in a quartz cell kept at 25 °C or 37 °C. Light
scattering measurements gave information on molecular mass of the
particles in solution and on their translational diffusion coefficient,
related to their hydrodynamic radius. DLS data were analyzed by both
the cumulants method, to detect the weight-average hydrodynamic size
of particles, and the non-negative least-squares (NNLS) method
(Lawson and Hanson, 1995), suitable to determine the size distribution
of EVs. EVs samples were prepared as described for NTA analysis and
observed by light scattering to verify the presence/absence of particles
in the same size range of EVs. All samples were diluted 1:10 with fil-
tered PBS to avoid multiple scattering.
2.9. Sphingolipid profile of EVs and MSCs
Sphingolipid extraction and LC–MS/MS evaluation were performed
according to the procedure already published elsewhere (Platania et al.,
2019). Briefly, in order to increase the recovery of low-abundance
sphingolipids, samples were extracted by a monophasic Bligh-Dyer
method with alkaline methanolysis. Purified samples (10 μL) were di-
rectly injected to LC–MS/MS instrumentation (UPLC Dionex 3000 Ul-
tiMate - Thermo Fisher Scientific, USA) connected to an ABSciex 3200
QTRAP - AB Sciex S.r.l., Milano, Italy) for quantitative analysis. Se-
paration was attained on a reversed-phase BEH C-8 10×2.1 x 1.7 μm
analytical column with a linear gradient obtained by mixing eluent A
(water +2mM ammonium formate + 0.2% formic acid) and eluent B
(methanol + μ ammonium formate + 0.2% formic acid). Multiple re-
action monitoring (MRM) mode was used. For ceramides and dihy-
droceramides quantitative analysis was performed interpolating each
peak area of analyte/area IS (200 pmol Cer C12) with a calibration
curve of each sphingolipid. For sphingomyelins, since the standards
were not available, relative quantification was achieved by the ratio of
the analyte/area IS (200 pmol SM C12). Then, sphingolipids amount
was normalized by total protein content, expressed in milligram, in
each sample.
Fig. 1. Effects of EVs derived from ctr and CF-MSCs on cytokines mRNA expression and protein release in IB3-1 cells. The mRNA expression was evaluated by RT-PCR
and the results reported as fold change over the control untreated IB3-1 cells. The cytokines content, expressed as picograms per mg of protein (pg/mg), was
measured by ELISA in culture media of IB3-1 cells. Panel A and B refer to IL-1β mRNA and protein; panel C and D, to IL-8 mRNA and protein; panel E and F, to IL-6
mRNA and protein, respectively. Control refers to untreated IB3-1 cells at basal condition; ctr EVs refers to cells treated for 24 h with EVs from control MSCs; CF-EVs
refers to cells treated for 24 h with EVs from CF-MSCs, meaning MSCs supplemented with 10 μg/ml of CFTR inhibitor, I-172, for 48 h. Data, expressed as
mean ± SEM, are obtained from seven individual MSCs - derived EVs populations. The samples were run in triplicate for RT-PCR or in duplicate for ELISA analysis.
Significance was evaluated by one-way ANOVA, followed by Newman-Keuls post-test. **, p < 0.01; *, p < 0.05.
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2.10. RNA extraction and quantitative RT-PCR
Real-time PCR was performed on RNA from control and ctr EVs and
CF-EVs-treated IB3-1 (2,5× 105 cells/well). RNA extraction and re-
verse transcription were performed as previously reported (Zulueta
et al., 2018). Human gene primer sequences for SPTLC 1, SPTLC 2,
SPTLC 3, nSMase2, PPARγ, IL-1β, IL-8, IL-6 and GAPDH were pre-
viously published (Zulueta et al., 2018; Hornemann et al., 2006; Kubota
et al., 2015; Dechecchi et al., 2011). RT-PCRs were performed on a
StepOnePlus Real-Time PCR Systems (Thermofisher). Results were
normalized on GAPDH and the 2-ΔΔCt method was used to calculate
the relative value of gene expression vs control cells (Arocho et al.,
2006). Determinations were done in triplicate.
2.11. Protein extraction and western blotting
Nuclear and cytoplasmic extracts from 5×105 IB3-1 cells, either
treated or not with EVs, were obtained with the NE-PER Nuclear and
Cytoplasmic Extraction Reagents kit (Thermo scientific) according to
the manufacturer's instructions, for PPARγ evaluation. To characterize
CFTR channel expression, whole cell lysates were prepared by trypsi-
nization of treated and control MSCs, washed in cold PBS containing
protease inhibitors, centrifuged at 800 g for 5min at 4 °C, and finally
resuspended in the same PBS solution. Equal amounts of nuclear (10 μg)
or cytoplasmic (20 μg) protein’s extracts were resuspended in Laemmli
solution, separated by electrophoresis and immunoblotted as previously
described (Fabiani et al., 2017). Anti-PPARγ (1:500 in TBS-T), anti HO-
1 (1:1000 in TBS-T), anti-caspase 9 (1:1000 in TBS-T), anti-LC3 (1:1000
in TBS-T), anti-β-Actin (1:5000 in TBS-T), and anti-H3 (1:500 in TBS-T)
antibodies were used. H3 and β-Actin contents were quantified for data
normalization of nuclear and cytoplasmic markers, respectively. Spe-
cific bands intensity, as revealed by chemiluminescence, was quantified
by Alliance UVITEC Cambridge.
2.12. ELISA determinations
The protein expression of the cytokines IL-1β, IL-6 and IL-8 was
determined in treated IB3-1 culture media by biomarker multiplex
immunoassays on Luminex® Platform. Cell protein concentration, was
calculated by Bradford assay and used for data normalization.
Determinations have been performed in duplicate.
2.13. Ferric reducing antioxidant power (FRAP) assay
The ferric reducing antioxidant power (FRAP) assay was performed
according to previously published method (Benzie and Strain, 1999)
with minor modifications (Zulueta et al., 2017).
2.14. Statistical analysis
Data significance was evaluated by paired two-tailed Student t-test
and by one-way ANOVA followed by the Newman-Keul post-test when
significant (P < 0.05). The results are the mean value (mean ± SEM)
from five to seven individual experiments, depending on the assay.
Either duplicate or triplicate samples for each treatment were per-
formed. Western blotting, light scattering and flow cytometry images
are the most representative. Statistical analysis was performed by
GraphPad Instat software (La Jolla, CA, USA) and graph illustrations by
GraphPad Prism software (La Jolla, CA, USA).
3. Results
3.1. EVs released from ctr- and CF-MSCs differently attenuate the pro-
inflammatory profile of IB3-1 cells
In order to investigate the hypothesis that lung MSCs and MSC-de-
rived EVs could be immunologically impaired in CF, we obtained an in
vitro model of CF-MSCs, by treating control MSCs with the specific
CFTR inhibitor, I-172 (Mattoscio et al., 2010). At first, we confirmed by
Western Blotting analysis that lung MSCs express CFTR protein as it is
shown in Supplementary Fig. 1. IB3-1 cells cultured in basal condition,
were treated for 24 h with 30 μL of EVs released from either I-172-
treated or untreated MSCs (namely CF-EVs or ctr EVs). The cell viability
was unaffected by the treatment with CF-EVs and neither signs of early
apoptosis nor of autophagy were increased as compared to the ctr EVs-
treated cells (Supplementary Fig. 2). Concerning the expression of pro-
inflammatory cytokines, following ctr EVs supplementation we ob-
served a trend toward a decrease in the mRNA and protein expression of
IL-1β, IL-8 and IL-6 vs control IB3-1 cells not supplemented (Fig. 1). IL-
1β seems the most responsive, showing a significant 35% reduction at
both the transcriptional and the protein level (Fig. 1, panel A;B) though
IL-6 protein amount moves from 95.4 ± 11.4 to 56.6 ± 2.5 pg/mg
protein, with a global 40% reduction (Fig. 1, panel F).
As a whole, CF-EVs seem less effective then ctr EVs in attenuating
the pro-inflammatory profile of IB3-1 cells. Both the mRNAs and the
proteins of the three cytokines slightly increased in the CF-EVs group as
compared to the ctr EVs group, though not significantly exceeding the
control basal level (Fig. 1). Notably, we observed significant differences
in IL-1 βmRNA (Fig. 1, panel A) and IL-6 protein (Fig. 1, panel F) which
are significantly higher in the CF-EVs treated group than in the ctr EVs
one. In fact, IL-1β mRNA rises by about 45% and IL-6 protein by 60%,
moving from 56.6 ± 2.5 to 90.49 ± 8.28 pg/mg protein.
Fig. 2. Morphological features of ctr and CF-EVs populations. Panel A shows an
example of Nanoparticle Tracking Analysis (NTA) representing the overall
distribution of the particles in ctr and CF-EV populations, according to their
mean size. On the cumulative plot, data are reported as percentage of particles
distributed within a mean size value, expressed as nm. Panel B reports an ex-
ample of Dynamic Light Scattering analysis showing the intensity weighted
distribution of hydrodynamic diameters for ctr EVs and CF-EVs. The black bars
and the corresponding black plotting curve refer to CF-EV. The gray bars and
the corresponding plotting curve refer to EVs from control MSCs. The graphs
are the most representative of four different analysis.
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We have recently demonstrated that PPARγ, which has an estab-
lished anti-inflammatory role, is up-regulated in the IB3-1 cell line upon
treatment with ctr MSCs-derived EVs (Zulueta et al., 2018). Conversely,
here we show that PPARγ transcript is unaffected by CF-EVs treatment,
being expressed as in the untreated control IB3-1 cells (Supplementary
Fig. 3), supporting the hypothesis of CF-EVs immunological impair-
ment. The EV treatment could interfere with the redox homeostasis of
IB3-1 cells, thus indirectly modulating the inflammation status (Sup-
plementary Fig. 4). Control-EVs increase the intrinsic antioxidant
power of IB3-1 cells, as shown by the rise in the Fe ions level in the
reduced form and by the up-regulation of HO-1 that is a master reg-
ulator of the redox-homeostasis. Conversely, CF-EVs treatment fails in
improving this protective response, as evidenced by the content of Fe
ions in the reduced form and HO-1 that are pretty near to the control
value.
3.2. EVs from ctr- and CF-MSCs show different features
We have already specified the composition of the EV population
released by human lung MSCs by the classical exosome and micro-
vesicle markers (Zulueta et al., 2018). In this project, we aimed at
characterizing ctr EV and CF-EVs in order to understand whether they
possess distinct features that might partially account for their different
anti-inflammatory potential.
We evaluated the amount of EVs and their size distribution by both
Nanoparticles Tracking Analysis (NTA) and Light Scattering. Fig. 2 re-
ports structural result of ctr EVs and CF-EVs prepared in serum-free
medium, as described in “material and methods” section, to better
characterize the differences among the two particle populations. The
cumulative frequency plot (Fig. 2, panel A) shows that ctr EVs exhibit a
wide regular distribution with approximately 80% particles distributed
within 340 nm in size (as indicated by the blue arrow). Conversely, CF-
EVs rather follow a Gaussian distribution that peaks at 150 nm, with
approximately 80% particles within 200 nm (as indicated by the red
arrow). Those results are in agreement with the mean hydrodynamic
size, as assessed by Dynamic Light Scattering (Fig. 2, panel B). As
shown, CF-EVs have a hydrodynamic size 20% smaller than the ctr EVs,
corresponding to about a 60% smaller volume per EV. Moreover, both
NTA and light scattering experiments determined that the number of
CF-EVs was approximately 1.5 times higher than the number of ctr EVs,
moving from 4.27×109±5.5×108 to 2.99× 109± 8.0× 108/ml
(NTA data, not shown). The combined results suggest that EVs released
by ctr MSCs and CF-MSCs, have a different supramolecular organiza-
tion, resulting in more numerous, but smaller CF-EVs.
To study the internalization rate of MSCs-derived EVs by IB3-1 cells,
we designed a quantitative flow cytometric assay, as reported in the
“Materials and methods” section. Control and CF-MSCs were labeled
with the CellBrite Cytoplasmic Membrane Dye, EVs were isolated and
used to treat IB3-1 cells and the uptake was assessed by flow cytometry
16 h later. Fig. 3 shows that CF-EVs are more efficiently internalized by
IB3-1 cells than ctr EVs, as indicated by the value of the fluorescence
intensity, normalized on the number of particles, with an increase of
almost 50% (from 531.3 ± 84.63–795.8 ± 177.3 ΔGeoMFI/EVs
number).
3.3. Sphingolipid profile is differently characterized in ctr EVs and CF-EVs
In an attempt to gain insights in the potential mediators underlying
the different anti-inflammatory behavior of ctr- and CF-EVs, we de-
termined the composition of SPLs that play a well-known role in
modulating inflammation. By means of LC–MS/MS analysis, we ob-
served a significant rise in the content of total Cer and dhCer, its pre-
cursor along the neo synthesis pathway, in CF-EVs vs ctr EVs, with value
ranging from 790.9 ± 76.3 to 991.1 ± 133.8 and from 18.17 ± 1.8
to 25.75 ± 3.7 pmoles/mg protein, respectively (Table 1).
When considering the single Cer species (Fig. 4, panel D), we found
that the most representative fatty acid containing Cer is the C16:0
which accumulates in CF-EVs 15% more than in ctr EVs. Moreover, the
ceramides bearing longer saturated and unsaturated fatty acid chains,
namely C20:0, C22:0, C24:0, and C24:1, significantly increased in CF-
EVs by 25%, 60%, 100%, and 25%, respectively. We observed the same
trend in the corresponding dhCer species. As shown in panel E, dhC16-
Fig. 3. Labeled EVs incorporation by IB3-1 cells. IB3-1 cells were seeded in 24-well culture plates and treated for 16 h with 100 μL of EVs derived from CellBrite
Green Cytoplasmic Membrane Dye-labeled MSCs. Panel A: representative graph of the fluorescence intensity values indicating the uptake rate of EVs. The black curve
represents the untreated cells; the blue curve represents cells incubated with ctr EVs and the red curve represents cells incubated with CF-EVs. Panel B: quantitative
determination of EVs uptake by IB3- 1 cells following 16 h of incubation. The gray and black bars represent the internalization value of EVs released from control and
CF-MSCs, meaning MSCs added with 10 μg/ml of CFTR inhibitor, I-172, for 48 h. Data are expressed as mean ± SEM of five independent experiments. The statistical
significance was evaluated by two-tailed, paired, Student t-test (*, P < 0.05) performed on the value of geometric mean fluorescent intensity subtracted of the
control untreated cells (ΔGeoMFI) and normalized on the number of particles (For interpretation of the references to colour in this figure legend, the reader is referred
to the web version of this article.).
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Cer rises by almost 30%, dhC24:0-Cer by more than twofold and
dhC24:1-Cer by 40%. As for SM, we found no significant differences in
the total (Table 1) and the single species expression (Fig. 4, panel F) but
only a trend toward a decrease in their level was apparent. As compared
to EVs, parental MSCs cells display a similar SPLs pattern. We observed
a significant 30% increase in the total Cer content (from
2605 ± 461.4–3387 ± 496.8 pmoles/mg protein; Table 1) and about
35% accumulation of the most representative fatty acid containing Cer,
namely C16:0, C22:0, and C24:0 (Fig. 4, panel A). On the contrary, total
(Table 1) and single dhCer species (Fig. 4, panel B) were similarly ex-
pressed in both MSC populations. Finally, we found a reduction in the
relative abundance of total and single SM species (Table 1; Fig. 4, panel
C).
Next, we checked whether the ctr and the CF-MSCs, could differ-
ently express the Serine palmitoyl transferase (SPT), the rate limiting
enzyme of the de novo ceramide biosynthesis pathway, and the neutral
sphingomyelinase 2 (n-SMase 2), highly involved in the biogenesis of
EVs. SPTLC-2 mRNA (panel A), one of the two catalytic subunits of SPT,
as well as n-SMase 2 (panel B) were significantly upregulated (*,
p= 0.04 and *, p= 0.02, respectively) in CF-MSCs as compared to ctr
MSCs (Fig. 5).
Fig. 4. Sphingolipid profile of ctr and CF-EVs and parental MSCs. Sphingolipid profile of EVs and parental MSCs was obtained by LC/MS analysis. Panel A and D
represent single Cer species content, expressed as pmoles/mg protein, in MSCs and EVs populations, respectively. Panel B and E show single dhCer species content,
reported as pmoles/mg protein, in MSCs and EVs populations, respectively. Panel C and F represent single SM species content, expressed as relative abundance, in
MSCs and EVs populations, respectively. The gray bars correspond to ctr MSCs and ctr EVs while the black bars refer to CF-MSCs and CF-EVs. Data are expressed as
mean ± SEM of five to seven independent experiments. The statistical significance was evaluated by two-tailed, paired, Student t-test (*, P < 0.05).
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4. Discussion
Our study focuses on determining whether MSCs could impact the
inflammatory chronic condition that characterizes Cystic Fibrosis. We
took advantage of an in vitro cellular model of CF-MSC by treating
control human lung MSCs with a specific CFTR inhibitor (I-172) in
order to obtain CF-EVs that mimic those particles physiologically re-
leased in the lung of CF patient. We used IB3-1, a transformed human
bronchial epithelial cell line from a CF patient (ΔF508/W1282X), to
gain the basal inflammatory CF phenotype (Armstrong et al., 1997;
Tirouvanziam et al., 2000) and we compared the anti-inflammatory
potential of CF-EVs with control EVs. As we previously published
(Zulueta et al., 2018), here we show that EVs from control MSCs at-
tenuate the pro-inflammatory profile of IB3-1 cell by reducing the cy-
tokines expression and rescuing the transcription of PPARγ, highly in-
volved in anti-inflammatory mechanisms. On the contrary, CF-EVs
treatment is less effective on cytokines and PPARγ expression, pro-
viding an explanation for the basal physiological inflammatory phe-
notype. Accordingly, Sutton and colleagues (Sutton et al., 2017) re-
cently showed that deficient CFTR function, achieved by the same CFTR
inhibitor (I-172), alters human MSCs ability to control the in-
flammatory response to pathogenic organisms. They indicate that CF-
MSCs do not behave similarly to control MSCs, due to the expression of
different amounts of IL-6, CCL2 and IL-8. Moreover, they observed that
by blocking CFTR activity in wild type bone marrow derived macro-
phages, PPARγ levels decrease.
Our results suggest that the two EVs populations released by the
parental MSCs, exhibit quite different features. CF-EVs are more
abundant and smaller than the ctr EVs and they are more efficiently up-
taken by the recipient IB3-1 cells. Growing evidence indicates that in-
flammatory conditions might trigger the release of EVs that in turn
maintain such condition. As reviewed by Cypryk and colleagues
(Cypryk et al., 2018), inflammasome activity correlates with enhanced
secretion of EVs and modulation of their mediators content. Murine
microglial cell line challenged with LPS, acquires an activated pro-in-
flammatory status that greatly increases the release of EVs. In contrast,
EV secretion was completely attenuated to control levels using a TNFα
inhibitor (Yang et al., 2018). In our experimental model, we did not
directly challenge MSCs with pro-inflammatory stimuli, but CF-MSCs
seem to be immunological impaired since CFTR activity inhibition is per
se correlated to inflammation (Sutton et al., 2017), thus enhancing EVs
secretion. Though the ESCRT machinery represents the general process
of exosomes release, in 2008 a Cer-mediated mechanism has been first
described (Trajkovic et al., 2008). The authors proposed SM hydrolysis
by n-SMase 2, the enzyme which mostly resides in the Golgi and ER,
and the consequent Cer generation as important players in exosomes
biogenesis. In fact, the cone-shaped structure of Cer spontaneously
drives the negative curvature of the membrane, favouring vesicles
formation. Consistently, the block of n-SMase reduces exosomes release
in various cell lines (Kosaka et al., 2010; Asai et al., 2015; Xu et al.,
2016). However, the same enzyme differentially controls the secretion
of larger EV population, such as MVs (Menck et al., 2017). We found a
significant decrease in the relative abundance of total SM in CF-MSCs
versus ctr MSCs, together with a transcriptional activation of n-SMase 2,
suggesting that this pathway could be involved in EVs production.
Therefore, the accumulation of Cer observed in both CF-EVs and
parental MSCs, could contribute to the abundancy of CF-EVs as com-
pared to ctr EVs. Ceramide formation upon SM hydrolysis, allows those
membrane changes required for the release of exosomes that are on
average smaller than MVs, thus accounting for the majority of CF-EVs
distributed within 150 nm in size, as compared to ctr EVs. In our model,
the significant accumulation of both Cer and dhCer species in CF-EVs
points to the involvement of the de novo Cer synthesis in the parental
CF-MSCs. This finding is further supported by the transcriptional up-
regulation of SPLTC-2, one of the two catalytic subunits of the SPT that
regulates the rate limiting step of the de novo pathway. Though CF-
MSCs exhibit unchanged dhCer levels, specific mechanisms of lipid
sorting into EVs that export out of the cells the SPLs generated could
occur (Podbielska et al., 2016). The higher content in dihydroceramides
of EVs in comparison to MSCs, suggests that the Cer biosynthesis up-
regulation is tightly linked to the extrusion of signaling lipids, deriving
from ER and including Cer precursor. Whereas this latter is rapidly
Table 1
Total sphingolipid content in ctr and CF-EVs and parental MSCs. Total Cer and
dhCer content was assessed by LC–MS/MS. The results are expressed as pmoles/
mg protein. For total SM content, relative quantification was achieved by the
ratio of the analyte/area IS (200 pmol SM C12). Data, reported as
mean ± SEM, are obtained from five to seven independent experiments. The
statistical significance was evaluated by two-tailed, paired, Student t-test.
Total Cer dhCer SM
pmoles/mg protein pmoles/mg protein relative abundance
Ctr MSCs 2605 ± 461.4
(n=5)
55.68 ± 13.1
(n= 5)
195.1 ± 30.7
(n= 5)
CF-MSCs 3387 ± 496.8
(n=5)
57.36 ± 15.9
(n= 5)
168 ± 30.2
(n= 5)
P=0.02 P=ns P=0.03
Ctr EVs 790.9 ± 76.3
(n=7)
18.17 ± 1.8
(n= 7)
98.24 ± 11.7
(n= 7)
CF-EVs 991.1 ± 133.8
(n=7)
25.75 ± 3.7
(n= 7)
90.87 ± 11.5
(n= 7)
P=0.04 P=0.01 P=ns
Fig. 5. mRNA expression of Serine palmitoyl transferase (SPT) and neutral sphingomyelinase 2 (n-SMase 2) in ctr and CF-MSCs. Control MSCs (ctr MSCs, gray bar)
refer to untreated MSCs while CF-MSCs (black bar), refer to control MSCs treated for 48 h with 10 μg/ml of CFTR inhibitor, I-172. The results are expressed as fold
change over the control MSCs. Data, reported as mean ± SEM, are obtained from five independent experiments. For each treatment, the samples were run in
triplicate. The statistical significance was evaluated by two-tailed, paired, Student t-test.
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dehydrogenated along with ER reactions, its early compartmentaliza-
tion in multi-vesicular bodies may fuel extracellular lipid signaling in
the effort of controlling lipid cellular homeostasis. Our results indicate
that the inflammation activated Cer de novo synthesis and accumulation
(Caretti et al., 2014; Caretti et al., 2016) trigger a transcriptionally
driven response that requires higher sphingomyelinase activity to sus-
tain the release of new formed ceramide throughout the exocytosis of
vesicles that spread their originating inflammatory-alarm signal.
It has been reported that Cer-enriched exosomes mediate cytotoxic
effects in recipient cells. Podbielska and colleagues (Podbielska et al.,
2016) demonstrated that HOG, an oligodendroglioma cell line, re-
sponds to cytotoxic cytokines by eliciting the release of Cer-enriched
exosomes. They support the idea that vesicular Cer contributes per se to
the toxic effects elicited by the cytokines. This is consistent with pre-
vious studies illustrating that many dangerous effects of TNFα on dif-
ferent subsets of cells are mediated by Cer generation (Osawa et al.,
2005; White-Gilbertson et al., 2009). Similarly, we have previously
published that Cer from de novo biosynthesis pathway contributes to
lung inflammation in CF murine models, upon infection with P. aeru-
ginosa and A. fumigatus (Caretti et al., 2014; Caretti et al., 2016). Our
present results corroborate these data since we found an inverse cor-
relation between the anti-inflammatory efficacy of EVs and their Cer
content.
5. Conclusion
In conclusion, our findings support the hypothesis that CFTR dys-
function, obtained by treating control MSCs with a specific CFTR in-
hibitor, associates with an enhanced sphingolipid metabolism leading
to an increase in the content of ceramide. This in turn promotes the
release of CF-EVs that export the excess of pro-inflammatory ceramide
to the recipient cells, thus contributing to maintain the chronic, un-
resolved inflammatory status of Cystic Fibrosis. These results contribute
to better elucidate the role of Cer-enriched EVs in Cystic Fibrosis,
providing the rationale for novel therapeutic approaches.
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